Funding Sources

  1. Research Funding Program: Thales. Investing in knowledge society through the European Social Fund Union (European Social Fund – ESF) and Greek national funds through the Operational Program; Co-financed by the European “Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF).
  2. Marie Skłodowska-Curie Research and Innovation Staff Exchange Funded by H2020, MSCA-RISE-2014 action[Grant Agreement number: 645756 — GLYCANC — H2020-MSCA-RISE-2014] for the Action: "Matrix glycans as multifunctional pathogenesis factors and therapeutic targets in cancer". Collaborators: Westfaelische Wilhelms University of Muenster, University of Reims Champagne-Ardenne, University of Insubria, University of Uppsala, National Center for Scientific Research “Demokritos”, Serend-IP GmBH, Fidia Farmaceutici SPA, Semmelweis Egyetem, Cairo University.
  3. "Νανοβιοτεχνολογική ενέσιμη εξωκυττάρια μήτρα ( ECM ) για αναγέννηση χόνδρου, εξατομικευμένη θεραπεία και ταυτοποίηση μεταβολιτών του «ατομικού» μικροβιώματος που εμπλέκονται στον εκφυλισμό των αρθρώσεων "ArthroMicroPerMed" Τ1ΕΔΚ-04567 της δράσης «ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ», 2018-.
  4. MIZUTANI FOUNDATION FOR GLYCOSCIENCE, “THE 20TH RESEARCH GRANT 2013” “Biological roles of serglycin in breast cancer”.